We read with interest the article by Nayak *et al.* \[[@bib1]\] published in a recent issue of the *Journal of the Endocrine Society* in which the authors sought to evaluate the incidence of diabetes insipidus (DI) after pituitary adenoma resection and assessed for preoperative risk factors that were associated with postoperative DI. Nayak *et al.* \[[@bib1]\] concluded that patients with pituitary adenoma presenting with visual abnormalities, suprasellar extension, or large tumors are at higher risk of developing postoperative DI.

However, our main concern is with the diagnostic approach to and definition of permanent DI. Nayak *et al.* \[[@bib1]\] define patients with permanent DI as those who still need to use desmopressin based solely on persistent DI symptoms after \>3 months, without any testing or objective evaluation for the presence of DI.

Adams *et al.* \[[@bib2]\] reported ≤80% of postoperative DI resolution with a mean time to resolution of 2.9 months (±4.9 SD), and the last DI resolution registered after 18 months of follow-up. Based on this fact, several studies recommend that patients must stop their DI medication weekly during a 6-month postsurgery period, to assess for DI symptoms and therefore decide upon continuation of the therapy, classifying these patients with permanent DI \[[@bib2], [@bib3]\]. Nevertheless, this approach could have a recall bias, which could underestimate or overestimate the incidence of permanent DI cases. Moreover, the fact that the current study evaluated only \>3 months of follow-up (instead of \>6 months as recommended) adds to the possible overestimation of permanent DI cases.

By reassessing the patients' urinary and serum osmolality and serum sodium at the last follow-up, this bias could had been avoided. Additional studies should evaluate patients not only clinically but also with laboratory tests to determine whether patients can be categorized as having permanent DI.
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